Laurantis Pharma, Ark Therapeutics Sign Manufacturing Agreement
UK Ark Therapeutics has been selected to manufacture and supply Lymfactin to Laurantis Pharma under a conditional agreement announced today by the Finland-based companies.
The agreement is subject to Laurantis receiving regulatory approval to commence its phase I clinical trial. Specific terms of the agreement are not disclosed.
Lymfactin uses an adenoviral vector to deliver vascular endothelial growth factor (VEGF-C) during transplantation of lymph nodes in order to avoid lymphedema.
